Log in

LON:SUMMSummit Therapeutics Share Price, Forecast & News

GBX 20.50
0.00 (0.00 %)
(As of 02/21/2020)
Add
Compare
Today's Range
18
Now: GBX 20.50
20.50
50-Day Range
20.50
MA: GBX 20.50
20.50
52-Week Range
18
Now: GBX 20.50
30
Volume268,382 shs
Average Volume34,608 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Read More
Summit Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.55 out of 5 stars


Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1235-443939

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive SUMM News and Ratings via Email

Sign-up to receive the latest news and ratings for SUMM and its competitors with MarketBeat's FREE daily newsletter.

Summit Therapeutics (LON:SUMM) Frequently Asked Questions

How has Summit Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Summit Therapeutics' stock was trading at GBX 20.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SUMM stock has increased by 0.0% and is now trading at GBX 20.50. View which stocks have been most impacted by Coronavirus.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics PLC (LON:SUMM) announced its quarterly earnings results on Wednesday, June, 12th. The company reported ($3.00) EPS for the quarter, topping analysts' consensus estimates of ($4.00) by $1.00. View Summit Therapeutics' earnings history.

Has Summit Therapeutics been receiving favorable news coverage?

News articles about SUMM stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Summit Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutSummit Therapeutics.

Who are some of Summit Therapeutics' key competitors?

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include SUMMIT THERAPEU/S (SMMT), American Airlines Group (AAL), Acadia Healthcare (ACHC), Avesoro Resources (ASO), Diana Shipping (DSX), Jelf Group (JLF), National Fuel Gas (NFG), Tailored Brands (TLRD), Weir Group (WEIR) and Acacia Mining (ABGLF).

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the following people:
  • Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)
  • Mr. Erik Ostrowski, Chief Financial Officer (Age 46)
  • Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)
  • Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)
  • Ms. Michelle Avery, Director of Investor Relations

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."

How do I buy shares of Summit Therapeutics?

Shares of SUMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Summit Therapeutics' stock price today?

One share of SUMM stock can currently be purchased for approximately GBX 20.50.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is www.summitplc.com.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136A Eastern Avenue, ABINGDON, OX14 4SB, United Kingdom. The company can be reached via phone at +44-1235-443939.

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.